Sandoz launches Zarxio biosimilar

Drug maker Sandoz has officially launched its Zarxio (filgrastim-sndz) biosimilar after a US appeals court declined to issue an injunction that would have prevented it from being sold.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit denies rehearing in ‘patent dance’ case

19 October 2015 The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.

Americas

‘Patent dance’ ruling leaves lawyers in a spin

23 July 2015 The US Court of Appeals for the Federal Circuit’s decision in Amgen v Sandoz is what the biosimilar industry would have been hoping for but clarity is lacking in several areas, lawyers have told LSIPR.

Americas

Federal Circuit says ‘patent dance’ is optional

22 July 2015 The US Court of Appeals for the Federal Circuit has ruled that biosimilar applicants can opt out of the so-called patent dance, paving the way for Sandoz to sell a biosimilar version of an Amgen drug.